Drug Central

Target result:

Accession: Q28731
Swissprot: Q28731_RABIT
Organism: Oryctolagus cuniculus
Gene: thrombin
Target class: Unclassified

Drug results: 9

dabigatran etexilate	A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
apixaban	Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
vorapaxar	Vorapaxar is a reversible antagonist of the protease-activated receptor-1 (PAR-1) expressed on platelets, but its long half-life makes it effectively irreversible. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation in vitro studies. Vorapaxar does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic and does not affect coagulation parameters ex vivo. PAR-1 receptors are also expressed in a wide variety of cell types, including endothelial cells, neurons, and smooth muscle cells, but the pharmacodynamic effects of vorapaxar in these cell types have not been assessed.
betrixaban	Betrixaban is an oral FXa inhibitor that selectively blocks the active site of FXa and does not require a cofactor (such as Anti-thrombin III) for activity. Betrixaban inhibits free FXa and prothrombinase activity. By directly inhibiting FXa, betrixaban decreases thrombin generation. Betrixaban has no direct effect on platelet aggregation.
bivalirudin	designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition
nafamostat	inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic; RN given refers to parent cpd
ximelagatran
turoctocog alfa pegol	Turoctocog alfa pegol is a purified recombinant human factor VIII (rFVIII) product with a 40 kDa polyethylene-glycol (PEG) conjugated to the protein. The PEG is attached to the O-linked glycan in the truncated B-domain of rFVIII (turoctocog alfa). The mechanism of action of turoctocog alfa pegolis based on the replacement of the deficient or absent factor VIII in patients with haemophilia A.When turoctocog alfa pegol is activated by thrombin at the site of injury, the B-domain containing the PEG moiety and the a3-region are cleaved off, thus generating activated recombinant factor VIII (rFVIIIa) which is similar in structure to native factor VIIIa.
gabexate	A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research

Drugs in the News

Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine

DrugCentral Search Overview

Drug search example:

Generic drug names, drug synonyms, trade names terms can be used to search for drugs. Example search for Lipitor can query using either “Atorvastatin” or “Lipitor”.A comprehensive list of drug development codes and salt or ester forms are also stored in the database and can be used as search terms, for example search for "rosuvastatin" the following terms can be used: "rosuvastatin calcium" or "ZD4522".

Disease search example:

Supported disease terms are SNOMED-CT and OMOP vocabulary terms. Disease annotations for drugs approved before 2012 originate from OMOP vocabulary mappings. For drugs approved after 2012 disease annotations are extracted manually from approved drug labels and mapped to SNOMED-CT concepts.

Example search for “Chronic Hepatitis C” returns the list of antiviral drugs indicated to treat “Chronic Hepatitis C” followed by drugs contra-indicated in hepatitis C.

New! Medical (off label) uses suggestion form
Off label Uses Form
New! Substructure Search:
The current update supports chemical substructure searching. Typing a SMILES string in the DrugCentral Substructure search bar launches a chemical substructure search that finds matching compounds in DrugCentral. E.g., N1cnccc1 . SMILES strings can be located on all Drug Cards under "Description".

New! FDA Adverse Event Reporting System:
The 2021 DrugCentral update, we separately calculated FAERS for men and women to enable research on sex differences in drug safety. The 2022 version goes further by computing adverse drug event scores granulated by age: pediatric data (FAERS_PED) covers patients from 1 day to 17 years, and geriatric data (FAERS_GER) focuses on elderly patients over 65 years of age, respectively. Female, Male, Geriatric & Pediatrics. E.g., amfetamine

New! Target Cards:
To perform a target card search enter a Uniprot target Accession ID e.g., P23975. The target cards depict the "Accession", "Swissprot", "Organism", "Gene" & "Target class" followed by "Drug relations" where the drugs "Bioactivity mechanism-of-actions" are identified.

Target search example:
Supported target search terms are HUGO gene symbols, Uniprot accessions and target names, and Swissprot identifiers. Example search for drugs targeting Mu-type opioid receptor can be run using either of the terms: “OPRM1”, P35372, “OPRM_HUMAN”, full or partial Uniprot target name. Returned drugs are ranked using the following criteria: top ranked drugs have mechanism of action target Mu-type opioid receptor, next in the list are drugs with potencies measured against this receptor.

In collaboration with the IDG
New! Veterinary Drugs, Uses & Products:

Drug Central now contains Veterinary Drugs, Uses & Products. The current update adds 1805 bioactivities for 226 veterinary drugs and 804 targets. DrugCentral veterinary data contains application numbers and types, trade names, applicant names, and prescription types for 1492 drug products as referenced in FDA’s Green Book. DrugCentral currently holds 1664 indications (pairs of drug and concept names) for 34 species. Dogs, cattle, and cats sum up to 63% of the indications covered by 193 veterinary drugs. Veterinary Drug Use can be found on each drug card by selecting the sub menu link: 🐶 Veterinary Use on the drug card. E.g., enrofloxacin
Pharmacologic action search example:

Supported pharmacologic action terms are MeSH, FDA [EPC, MoA, PE], ChEBI action roles.

Example search for “HMG-CoA Reductase Inhibitor” FDA EPC term for statin drugs returns list of all statin drugs classified by FDA as HMG-CoA reductase inhibitors.

Ranked result list is annotated with 4 level ranking system ordered from highest to lowest:

A - query term matched drug name or synonyms, mechanism of action target, or drug indication.

B - query term matched disease term in drug contraindications or off-label uses, targets listed in drug bioactivity profiles (not MoA targets), or pharmacologic action descriptions.

C - query term matched short drug description text.

D - query term matched full text in FDA drug labels.

Citing DrugCentral © 2024. License